1511 related articles for article (PubMed ID: 25977340)
1. Classifying Cancers Based on T-cell Infiltration and PD-L1.
Teng MW; Ngiow SF; Ribas A; Smyth MJ
Cancer Res; 2015 Jun; 75(11):2139-45. PubMed ID: 25977340
[TBL] [Abstract][Full Text] [Related]
2. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
D'Angelo SP; Shoushtari AN; Agaram NP; Kuk D; Qin LX; Carvajal RD; Dickson MA; Gounder M; Keohan ML; Schwartz GK; Tap WD
Hum Pathol; 2015 Mar; 46(3):357-65. PubMed ID: 25540867
[TBL] [Abstract][Full Text] [Related]
4. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Aoki T; Hino M; Koh K; Kyushiki M; Kishimoto H; Arakawa Y; Hanada R; Kawashima H; Kurihara J; Shimojo N; Motohashi S
Pediatr Blood Cancer; 2016 Aug; 63(8):1461-4. PubMed ID: 27135656
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Du Z; Abedalthagafi M; Aizer AA; McHenry AR; Sun HH; Bray MA; Viramontes O; Machaidze R; Brastianos PK; Reardon DA; Dunn IF; Freeman GJ; Ligon KL; Carpenter AE; Alexander BM; Agar NY; Rodig SJ; Bradshaw EM; Santagata S
Oncotarget; 2015 Mar; 6(7):4704-16. PubMed ID: 25609200
[TBL] [Abstract][Full Text] [Related]
6. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
7. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Peng J; Hamanishi J; Matsumura N; Abiko K; Murat K; Baba T; Yamaguchi K; Horikawa N; Hosoe Y; Murphy SK; Konishi I; Mandai M
Cancer Res; 2015 Dec; 75(23):5034-45. PubMed ID: 26573793
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
15. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Pagès F; Granier C; Kirilovsky A; Elsissy C; Tartour E
Bull Cancer; 2016 Nov; 103 Suppl 1():S151-S159. PubMed ID: 28057179
[TBL] [Abstract][Full Text] [Related]
17. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in small cell neuroendocrine carcinomas.
Schultheis AM; Scheel AH; Ozretić L; George J; Thomas RK; Hagemann T; Zander T; Wolf J; Buettner R
Eur J Cancer; 2015 Feb; 51(3):421-6. PubMed ID: 25582496
[TBL] [Abstract][Full Text] [Related]
19. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
20. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]